Efficacy and Safety of BBETTER SpineUrja in Managing Lower Back Pain and Sciatica: A Randomized, Double-Blind, Placebo-Controlled Study

This study is designed to evaluate the efficacy and safety of BBETTER SpineUrja in adults with mild to moderate lower back pain and sciatica. The study will be conducted as a randomized double blind placebo controlled clinical trial. Eligible participants aged 30 to 65 years will be randomly assigned to receive either BBETTER SpineUrja capsules or placebo capsules twice daily for a duration of eight weeks.

The primary objective of the study is to assess the effect of BBETTER SpineUrja on pain intensity using the Visual Analog Scale. Secondary objectives include evaluation of functional disability spinal mobility and quality of life using validated tools such as the Oswestry Disability Index Roland Morris Disability Questionnaire and Short Form 12. Safety will be assessed through monitoring of adverse events vital signs and laboratory investigations including inflammatory biomarkers and liver and kidney function parameters.

The hypothesis of this study is that BBETTER SpineUrja will significantly reduce lower back pain and sciatica symptoms improve functional outcomes and enhance quality of life compared to placebo while being safe and well tolerated.